Abstract
The purpose of this study was to determine whether acute pulmonary exacerbations of cystic fibrosis associated with nonbacterial infections are clinically distinguishable from other exacerbations. Eighty exacerbations in 54 patients were studied. Exacerbations associated with influenza (n=8) were compared with those associated with other nonbacterial infections (n=15) and those in which no nonbacterial infection was detected (n=57). Patients with influenza had lower Shwachman scores and were more likely to be seroposifive for C-reactive protein than patients in the other two groups. Patients with influenza had lower Shwachman scores and were more likely to be seropositive for C-reactive protein than patients in the other two groups. Patients with influenza had a mean decrease in forced expiratory volume per second of 26%, compared with test results obtained before the exacerbation. In contrast, the mean decrease in forced expiratory volume per second was 6% for other nonbacterial infections and 12% for the group without nonbacterial infection (p<0.05 for both comparisons). The forced expiratory flow in first 25% of vital capacity decreased 44% in the influenza group compared with 13% and 17% in the other two groups, respectively (p<0.01 for both comparisons). The influenza group also had a higher proportion of patients with at least a 20% decrease in forced expiratory volume per second and forced expiratory flow in first 25% of vital capacity than the other two groups had (p<0.05 for all comparisons). These data suggest that influenza is associated with severe exacerbations in patients with cystic fibrosis and support recommendations for efforts to prevent influenza in this population.
References
- 1.Stroobant J. Viral infection in cystic fibrosis. J R Soc Med. 1986;79(suppl 12):19–22. [PMC free article] [PubMed] [Google Scholar]
- 2.Petersen NT, Hoiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia, and mycoplasma-possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981;70:623–628. doi: 10.1111/j.1651-2227.1981.tb05757.x. [DOI] [PubMed] [Google Scholar]
- 3.Efthimiou J, Hodson ME, Taylor P, Batten JC. Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis. Thorax. 1984;39:150–154. doi: 10.1136/thx.39.2.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Wright PF, Oxman MT, Shwachman H. Evaluation of the safety of amantadine·HCl and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis. 1976;134:144–149. doi: 10.1093/infdis/134.2.144. [DOI] [PubMed] [Google Scholar]
- 5.Wang EEL, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984;311:1653–1658. doi: 10.1056/NEJM198412273112602. [DOI] [PubMed] [Google Scholar]
- 6.Ramsey BW, Gore EJ, Smith AL, Cooney MK, Redding GJ, Foy H. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child. 1989;143:662–668. doi: 10.1001/archpedi.1989.02150180040017. [DOI] [PubMed] [Google Scholar]
- 7.Hordvik NL, König P, Hamory B. Effects of acute viral respiratory tract infections in patients with cystic fibrosis. Pediatr Pulmonol. 1989;7:217–222. doi: 10.1002/ppul.1950070406. [DOI] [PubMed] [Google Scholar]
- 8.Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis: studies made over a five-to fourteen-year period. Am J Dis Child. 1958;96:6–15. doi: 10.1001/archpedi.1958.02060060008002. [DOI] [PubMed] [Google Scholar]
- 9.Brasfield D, Hicks G, Soong S, Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatr. 1979;63:24–29. [PubMed] [Google Scholar]
- 10.Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal α-2b interferon. J Infect Dis. 1986;154:443–447. doi: 10.1093/infdis/154.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Smith AL. Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. J Pediatr. 1986;108:866–870. doi: 10.1016/s0022-3476(86)80759-4. [DOI] [PubMed] [Google Scholar]
- 12.Gold R, Carpenter S, Heurter H, Corey, Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerations in patients with cystic fibrosis. J Pediatr. 1987;111:907–913. doi: 10.1016/s0022-3476(87)80217-2. [DOI] [PubMed] [Google Scholar]
- 13.Wood RE, Leigh MW. What is a “pulmonary exacerbation” in cystic fibrosis? J Pediatr. 1987;111:841–842. doi: 10.1016/s0022-3476(87)80198-1. [DOI] [PubMed] [Google Scholar]
- 14.McCarthy PL, Frank AL, Ablow RC, Masters SJ, Dolan TF., Jr. Value of the C-reactive protein test in the differentiation of bacterial and viral pneumonia. J Pediatr. 1978;92:454–456. doi: 10.1016/s0022-3476(78)80448-x. [DOI] [PubMed] [Google Scholar]
- 15.Glass S, Hayward C, Govan JRW. Serum C-reactive protein in assessment of pulmonary exacerbations and antimicrobial therapy in cystic fibrosis. J Pediatr. 1988;113:76–79. doi: 10.1016/s0022-3476(88)80533-x. [DOI] [PubMed] [Google Scholar]
- 16.Moreton RE, Kennedy CR. C-reactive protein concentrations in cystic fibrosis. Arch Dis Child. 1988;63:958–960. doi: 10.1136/adc.63.8.958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Glezen WP. The pediatrician's role in influenza control. Pediatr Infect Dis. 1986;5:615–618. doi: 10.1097/00006454-198611000-00001. [DOI] [PubMed] [Google Scholar]